Client News
Destiny Pharma: Interim results for the six months ended 30 June 2023
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities
Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis
Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
